Kenny Logan shares how he overcame erectile dysfunction after prostate cancer treatment
The former Scottish rugby union player was diagnosed with the condition in 2022 and underwent a full prostatectomy, a surgical procedure to remove the prostate gland.
Logan, who is married to BBC sports presenter Gabby Logan, said in a new interview that doctors warned him he might experience erectile dysfunction for some time after the treatment – and that his sex life was 'inconsistent for a good three months' following surgery.
'That's a huge deal for any man,' Logan told The Telegraph. 'But don't let fear or stigma get in the way. As I said to Gabby: 'Let's just deal with me getting cancer-free. Then we can deal with the sex part.''
Logan said the thing that helped most was a penis vacuum pump, which can increase blood flow to help achieve or maintain an erection.
'I used it for 10 minutes a day or so – several times in that first month. [I was] grateful that Gabby was away working on the Commonwealth Games.
'I warned her that if she ever walked in on me using it and didn't back straight out the door, I'd never speak to her again,' he joked.
Logan added that one of the biggest causes of erectile dysfunction (ED) is psychological, so he knew that fearing it would only make it more likely.
The sports star added: 'And let's be honest, ED is something that all men can struggle with, especially in their 50s – prostate or no prostate. It's not a massive deal and there's many other ways to enjoy being together in bed.'
'If it doesn't work, don't panic. Having a partner who can laugh about it helps massively. The biggest barrier is in your head – relax.'
Logan was diagnosed with prostate cancer, with no symptoms or family history of the disease, after having his Prostate Specific Antigen (PSA) levels monitored by a doctor when he found out they were abnormal at a private check-up.
The doctor told him not to worry, saying: 'Probably 40 per cent of your mates will have high levels too; they just aren't aware of it yet.'
By February 2022, his PSA level had risen to over seven, and he underwent a biopsy, which confirmed he had prostate cancer.
He said: 'That news left me and Gabby reeling. I've played sports all my life so I'm fit, I eat well and have never smoked. I've mostly drunk in moderation. Yet, as the doctor said to me, prostate cancer isn't caused by lifestyle, there is nothing to 'blame', and what's more, it's often entirely symptomless, as mine had been.
'I was two months shy of my 50th birthday at that time, I felt entirely well, and it was all such a shock that I almost fell over.'
Logan said he is now raising awareness of the disease, and that men often come up to him to discuss their own experiences.
'It happens in the strangest of places, whether I'm standing at a urinal in a pub or visiting a National Trust garden with Gabby,' he said. 'Like me, they've generally had a brush with prostate cancer and want to swap notes. I try to be honest and reassuring. I never expected my sex life at 53 to be of any interest!'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
26 minutes ago
- Forbes
Truckin' To 2030: Europe's Green Horizon For Medical Cannabis & Hemp
Europe's cannabis sector is undergoing a profound transformation—one driven by evolving regulations, changing social attitudes, and rising institutional investor interest. Germany, as the continent's largest economy, stands at the heart of this transition, leading a dual trajectory in both medical cannabis and industrial hemp. What was once niche is now positioned as a cornerstone of sustainable health, clean materials, and innovative investment opportunities. You might say that the European industry appears to be built to last. Market Overview and Segmentation Europe's cannabis landscape is divided into two distinct segments: THC‑containing cannabis (above 0.3% THC), regulated primarily for medical and sometimes adult-use purposes; and industrial hemp (below 0.3% THC), employed in foods, textiles, bioplastics, cosmetics, and construction. While sharing a botanical origin—Cannabis sativa L.—each operates under its own regulatory framework, supply chain, and market focus. Understanding this segmentation is essential for investors and policymakers evaluating risk and opportunity. Globally, the medical cannabis market was valued at approximately €4.5 billion in 2024 and is projected to reach over €62 billion by 2030—recording a staggering compound annual growth rate (CAGR) of 55%. Europe, fueled by demographic shifts and legal liberalization, is forecasted to be the fastest-growing region. Meanwhile, the industrial hemp market is poised to triple to around €15 billion by 2030, according to UNCTAD projections, driven by surging demand for climate-friendly materials and plant-based nutrition. Regulatory Developments The eyes of the world are on Germany, as it has emerged as the regulatory focal point in Europe. Its Cannabis Act (CanG), enacted in 2024, removed restrictive quotas and significantly expanded medical access. A complementary Medical Cannabis Act (MedCanG) is under development, emphasizing pharmacy-based distribution while tightening telemedicine channels. In parallel, a new Industrial Hemp Liberalization Act is expected in 2026, poised to eliminate outdated restrictions and modernize hemp production regulation. On the EU level, the classification of CBD as a Novel Food is opening doors to wellness and nutrition markets previously inaccessible for hemp producers. Growth in Medical Cannabis Since medical cannabis legalization in 2017, German patient numbers have soared—with 300,000 individuals receiving prescriptions in 2024, estimated to grow to 840,000 in 2025. By 2030, the market is expected to reach €650 million. Innovations in formulation—such as high-purity extracts, dronabinol pills, and cannabinoid pastilles—are expanding therapeutic use across neurology, chronic pain, and oncology. Major operators like SYNBIOTIC SE are leading the charge, developing standardized dosage forms and investing in regulated production. Global companies such as Tilray, Aurora, OrganiGram, and Canada's Sanity Group (via its partnership with OrganiGram) are deepening their European presence, underlining the continent's rising magnetism for international cannabis investors. Industrial Hemp as a Sustainability Engine Industrial hemp, long undervalued, is now recognized as a strategic asset in Europe's green economy. German industrial hemp sales grew from €526 million in 2023 to a projected €3 billion by 2032 (CAGR ~22%). Applications range from hemp-protein powders to sustainable building insulation and biodegradable packaging. EU regulatory shifts—especially Novel Food approvals for CBD—further enable consumer-facing products. Companies such as Hempro International and new-era ventures targeting hemp-based construction materials and plant-based supplements illustrate the growing breadth of the market. Investment Opportunities and Strategic Challenges Europe is increasingly attractive to North American capital. SYNBIOTIC SE exemplifies a diversified strategy, combining medical cannabis and hemp under a unified corporate model. The publicly traded holding company expects revenues to climb from €26 million in 2025 to €47 million by 2027, with positive EBITDA forecasted in 2026. This dual exposure provides a hedge against regulatory divergence and price compression in either sector. David Hyde, founder and CEO of Hyde Advisory & Investments, plays a pivotal role in monitoring and facilitating cannabis investments in Germany. Through his firm's expert brokerage services, Hyde navigates complex regulatory frameworks, matches strategic partners, and helps investors identify high-quality medical cannabis assets in the German market. Drawing from his firm's insights, Hyde notes: Germany's medical cannabis market continues to grow, albeit more slowly than Australia's. While German market competition is increasing, there is lots of room for new brand/category entrants with proper market research, understanding of developed cannabis markets and the right distribution partner(s)." Several industry leaders are confident that Europe represents the next major frontier for cannabis investment. As Boris Jordan, Executive Chairman of Curaleaf, put it, '[Europe is the next big market for cannabis after the U.S.]' Meanwhile, Irwin Simon, CEO of Tilray, emphasizes the scale of the opportunity: 'Germany's de-scheduling of cannabis opens the path to new opportunities in a potential $3 billion medical market; the European Union medical cannabis market is now projected to become $45 billion.' Constantin von der Groeben, founder of Demecan, reflects on Germany's growth momentum: 'The market is on a constant growth that is overwhelming,' while Beau Whitney, head economist at Whitney Economics, sees a broader European transformation underway: 'We can expect an accelerated expansion in the EU of legalised cannabis… If countries reform quickly, then the EU could supplant the U.S. as the major leader in global cannabis reform.' Yet investors must navigate risks: regulatory uncertainty (especially around telemedicine and CBD policy), intense price competition as production scales, limited banking integration, and macroeconomic volatility. The fragmented legal landscape further complicates capital deployment in cannabis-related ventures. Why Legalization Is Working The legalization model in Europe—and particularly in Germany—has shown measurable success. Its framework promotes transparency, standards for safety and quality, and integration into conventional health systems. The emphasis on licensing, standardized extracts, and court-regulated pharmacies mirrors a methodical approach, providing market certainty for investors and patients alike. Moreover, reform frameworks that prioritize illicit-market conversion—such as transitioning traditional, unregulated growers into legal cooperatives—mirror best practices championed by analysts like Whitney Economics. This conversion aligns economic incentives, reduces social harms, and demonstrates the sustainability of the legal regime. Outlook to 2030 As of 2025, both medical cannabis and industrial hemp are poised to become multibillion-euro pillars of Europe's economy. By 2030, medical cannabis in Europe could exceed €10 billion, while industrial hemp ascends as an eco-driven mainstay. Companies rooted in innovation, regulatory compliance, and product diversification will lead market consolidation. Germany will remain the driving force behind this evolution—acting as the regulatory pioneer and investment hub for cannabis in Europe. Institutional and private investors seeking long-term value should consider pan-European platforms that bridge both cannabis segments, such as publicly traded SYNBIOTIC SE. Their IFRS-audited integrated model reflects the shift to a new chapter in medicine and an innovative sustainable economy. END NOTES: CanG Gesetz 2024 – UNCTAD 2022 – Cannabissciencetech 2024 – CannaMonitor 2025 – Credence Research – Grand View Research – IMARC Group – Luminorecruit 2025 – MJBizDaily 2024 – Novel Food – OrganiGram/Sanity Group 2024 – Research And Markets 2024 – Reuters 2024 – Statista – Weedman 2025 –


Bloomberg
an hour ago
- Bloomberg
Biogen Sees Potential in Combining Alzheimer's and Obesity Drugs
If Novo Nordisk A/S 's wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer's disease, Biogen Inc.'s Chief Executive Officer Chris Viehbacher doesn't see it as a roadblock for his company's medication. Rather, he sees it as an opportunity to potentially combine drugs and create a more potent therapy. 'As we look out over the next five years, we're probably going to see a treatment much like any other complex disease,' he said in an interview with Bloomberg News, meaning there will be 'different mechanisms of action that you need.'


Bloomberg
2 hours ago
- Bloomberg
UK Primary Health Properties Fends Off KKR Bid for Landlord Assura
Primary Health Properties Plc has prevailed in the fiercely contested takeover battle for rival landlord Assura Plc, a watershed deal that saw shareholders reject a cash offer from private equity in favor of remaining invested in a UK public company. The transaction will create the UK's largest publicly traded health care landlord, bringing together PHP's £2.81 billion ($3.8 billion) portfolio with Assura's £3.1 billion of assets to create the country's eighth most valuable real estate investment trust by market capitalization.